PDF(Pubmed)
Abstract：
Spinal cord injuries (SCIs) can lead to significant neurological deficits and lifelong disability, with far-reaching physical, psychological, and economic consequences for affected individuals and their families. Current treatments for SCIs are limited in their ability to restore function, and there is a pressing need for innovative therapeutic approaches. Stem cell therapy has emerged as a promising strategy to promote the regeneration and repair of damaged neural tissue following SCIs. This review article comprehensively discusses the potential of different stem cell types, such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem/progenitor cells (NSPCs), in SCI treatment. We provide an in-depth analysis of the unique advantages and challenges associated with each stem cell type, as well as the latest advancements in the field. Furthermore, we address the critical challenges faced in stem cell therapy for SCIs, including safety concerns, ethical considerations, standardization of protocols, optimization of transplantation parameters, and the development of effective outcome measures. We also discuss the integration of novel technologies such as gene editing, biomaterials, and tissue engineering to enhance the therapeutic potential of stem cells. The article concludes by emphasizing the importance of collaborative efforts among various stakeholders in the scientific community, including researchers, clinicians, bioengineers, industry partners, and patients, to overcome these challenges and realize the full potential of stem cell therapy for SCI patients. By fostering such collaborations and advancing our understanding of stem cell biology and regenerative medicine, we can pave the way for the development of groundbreaking therapies that improve the lives of those affected by SCIs.
摘要：
脊髓损伤（SCIs）可导致严重的神经功能缺损和终身残疾，具有深远的物理意义，心理,以及对受影响的个人及其家庭造成的经济后果。目前对SCIs的治疗方法在恢复功能的能力方面受到限制，迫切需要创新的治疗方法。干细胞疗法已成为促进SCI后受损神经组织再生和修复的有希望的策略。这篇综述文章全面讨论了不同干细胞类型的潜力，如胚胎干细胞（ESC），诱导多能干细胞（iPSCs），间充质干细胞(MSCs),和神经干/祖细胞（NSPCs），在SCI治疗中。我们深入分析了与每种干细胞类型相关的独特优势和挑战，以及该领域的最新进展。此外，我们解决了SCIs干细胞治疗面临的关键挑战，包括安全问题，伦理考虑，协议的标准化，移植参数的优化，并制定有效的结果措施。我们还讨论了基因编辑等新技术的整合，生物材料,和组织工程，以增强干细胞的治疗潜力。文章最后强调了科学界各利益攸关方协作努力的重要性,包括研究人员,临床医生,生物工程师,行业合作伙伴,和病人，克服这些挑战，充分发挥干细胞治疗SCI患者的潜力。通过促进这种合作，提高我们对干细胞生物学和再生医学的理解，我们可以为开发突破性的疗法铺平道路，改善受SCIs影响的人的生活。
